NetraMark to Showcase AI in Psychiatry at ASCP Annual Meeting
Event summary
- NetraMark will present at the ASCP Annual Meeting in Miami from May 26-29, 2026.
- Founder Dr. Joseph Geraci will participate in a plenary panel on AI in psychiatry on May 28.
- Two scientific posters will demonstrate NetraAI's application in neuropsychiatric clinical development.
- Posters focus on ketamine response in treatment-resistant depression and predictive enrichment for esmethadone.
The big picture
NetraMark's participation at the ASCP Annual Meeting highlights the growing importance of AI in addressing clinical heterogeneity in psychiatric drug development. The company's focus on explainable AI and precision medicine aligns with industry trends toward more targeted and effective clinical trial designs. Success in this space could position NetraMark as a key player in transforming neuropsychiatric clinical development.
What we're watching
- AI Adoption
- How NetraMark's explainable AI approach will gain traction in neuropsychiatric drug development.
- Regulatory Alignment
- Whether the company's predictive enrichment methodology will meet regulatory standards.
- Market Differentiation
- The pace at which NetraMark can establish itself as a leader in AI-driven clinical trial optimization.
Related topics